Rivastigmine D6
- $305 - $640
- Product name: Rivastigmine D6
- CAS: 194930-00-2
- MF: C18H28N2O8
- MW: 400.43
- EINECS:
- MDL Number:MFCD28900699
- Synonyms:Rivastigmine D6;[2H6]-Rivastigmine tartrate;(S)-(-)-Rivastigmine-d6 L-Tartrate (N,N-dimethyl-d6);[2H6]-(R)-Rivastigmine Tartrate Salt;[2H6]-(R)-Rivastigmine tartrate;(S)-Rivastigmine D6 tartrate;Gallic Acid Impurity 7;(S)-Rivastigmine D6 Tartrate Salt
3 prices
Selected condition:
Brand
- AK Scientific
- Cayman Chemical
Package
- 500μg
- 1mg
- ManufacturerAK Scientific
- Product number0119DY
- Product description[3-[(1S)-1-[Bis(trideuteriomethyl)amino]ethyl]phenyl]N-ethyl-N-methylcarbamate;(2R,3R)-2,3-dihydroxybutanedioicacid
- Packaging1mg
- Price$640
- Updated2021-12-16
- Buy
- ManufacturerCayman Chemical
- Product number25633
- Product descriptionRivastigmine-d6 (tartrate) ≥99% deuterated forms (d1-d6)
- Packaging500μg
- Price$305
- Updated2024-03-01
- Buy
- ManufacturerCayman Chemical
- Product number25633
- Product descriptionRivastigmine-d6 (tartrate) ≥99% deuterated forms (d1-d6)
- Packaging1mg
- Price$486
- Updated2024-03-01
- Buy
Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
---|---|---|---|---|---|---|
AK Scientific | 0119DY | [3-[(1S)-1-[Bis(trideuteriomethyl)amino]ethyl]phenyl]N-ethyl-N-methylcarbamate;(2R,3R)-2,3-dihydroxybutanedioicacid | 1mg | $640 | 2021-12-16 | Buy |
Cayman Chemical | 25633 | Rivastigmine-d6 (tartrate) ≥99% deuterated forms (d1-d6) | 500μg | $305 | 2024-03-01 | Buy |
Cayman Chemical | 25633 | Rivastigmine-d6 (tartrate) ≥99% deuterated forms (d1-d6) | 1mg | $486 | 2024-03-01 | Buy |
Properties
storage temp. :Store at -20°C
solubility :DMF: 25 mg/ml; DMSO: 16 mg/ml; Ethanol: 16 mg/ml; PBS (pH 7.2): 10 mg/ml
form :A solid
color :White to off-white
solubility :DMF: 25 mg/ml; DMSO: 16 mg/ml; Ethanol: 16 mg/ml; PBS (pH 7.2): 10 mg/ml
form :A solid
color :White to off-white
Safety Information
Symbol(GHS): | ||||||||
---|---|---|---|---|---|---|---|---|
Signal word: | ||||||||
Hazard statements: |
|
|||||||
Precautionary statements: |
|